Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Section for Lymphoma and Medicine

13 publications found

Autio M, Leivonen SK, Brück O, Mustjoki S, Jørgensen JM, Karjalainen-Lindsberg ML, Beiske K, Holte H, Pellinen T, Leppä S (2020)
Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
Haematologica (in press)
DOI 10.3324/haematol.2019.243626, PubMed 32079690

Fosså A, Smeland KH, Fluge Ø, Tronstad KJ, Loge JH, Midttun Ø, Ueland PM, Kiserud CE (2020)
Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue
PLoS One, 15 (1), e0227384
DOI 10.1371/journal.pone.0227384, PubMed 31923274

Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC (2020)
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Br J Haematol, 189 (4), 661-671
DOI 10.1111/bjh.16425, PubMed 32017050

Kimby E, Lockmer S, Holte H, Hagberg H, Wahlin BE, Brown P, Østenstad B (2020)
The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy
Br J Haematol
DOI 10.1111/bjh.16692, PubMed 32410260

Leppä S, Jørgensen J, Tierens A, Meriranta L, Østlie I, de Nully Brown P, Fagerli UM, Larsen TS, Mannisto S, Munksgaard L, Maisenhölder M, Vasala K, Meyer P, Jerkeman M, Björkholm M, Fluge Ø, Jyrkkiö S, Liestøl K, Ralfkiaer E, Spetalen S, Beiske K, Karjalainen-Lindsberg ML, Holte H (2020)
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Blood Adv, 4 (9), 1906-1915
DOI 10.1182/bloodadvances.2020001518, PubMed 32380536

Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, Salles GA, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam CS (2020)
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma
Blood Adv, 4 (4), 629-637
DOI 10.1182/bloodadvances.2019001026, PubMed 32074277

Maaland AF, Saidi A, Torgue J, Heyerdahl H, Stallons TAR, Kolstad A, Dahle J (2020)
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003
PLoS One, 15 (3), e0230526
DOI 10.1371/journal.pone.0230526, PubMed 32187209

Regine K, Wittig T, Georgi TW, Kurch L, Sabri O, Wallace WH, Klekawka T, Fernández-Teijeiro A, Ceppi F, Karlén J, Pears J, Cepelová M, Fosså A, Beishuizen A, Hjalgrim LL, Körholz D, Mauz-Körholz C, Hasenclever D (2020)
Comparison of interim PET response to second-line vs. to first-line treatment in classical Hodgkin lymphoma - contribution to the development of response criteria for relapsed or progressive disease
J Nucl Med (in press)
DOI 10.2967/jnumed.120.247924, PubMed 32764122

Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø (2020)
Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study
Front Med (Lausanne), 7, 162
DOI 10.3389/fmed.2020.00162, PubMed 32411717

Rodrigues JM, Hassan M, Freiburghaus C, Eskelund CW, Geisler C, Räty R, Kolstad A, Sundström C, Glimelius I, Grønbaek K, Kwiecinska A, Porwit A, Jerkeman M, Ek S (2020)
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
Br J Haematol (in press)
DOI 10.1111/bjh.17023, PubMed 32748433

Tveiten H, Lehne G, Aukrust P, Lehne G, Skjonsberg OH (2020)
A man in his forties with increasing shortness of breath
Tidsskr. Nor. Laegeforen., 140 (6), 578-581

Tveiten H, Lehne G, Aukrust P, Rodriguez JR, Skjønsberg OH (2020)
A man in his forties with increasing shortness of breath
Tidsskr Nor Laegeforen, 140 (6)
DOI 10.4045/tidsskr.19.0692, PubMed 32321231

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Adv, 4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

 
Page visits: 423277